Ophthotech Corp (NASDAQ:OPHT) has received a consensus recommendation of “Buy” from the four brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $3.63.
A number of analysts recently issued reports on OPHT shares. Zacks Investment Research raised Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective on the stock in a report on Monday, November 13th. TheStreet raised Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th. Finally, ValuEngine cut Ophthotech from a “buy” rating to a “hold” rating in a report on Sunday, December 31st.
Shares of Ophthotech (NASDAQ OPHT) traded down $0.09 on Wednesday, reaching $2.67. The company had a trading volume of 257,943 shares, compared to its average volume of 401,895. The stock has a market cap of $96.40, a PE ratio of 1.71 and a beta of 1.43. Ophthotech has a twelve month low of $2.24 and a twelve month high of $4.81.
Large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its holdings in shares of Ophthotech by 182.2% in the 4th quarter. Wells Fargo & Company MN now owns 33,160 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 21,411 shares in the last quarter. Alambic Investment Management L.P. bought a new position in shares of Ophthotech during the 4th quarter valued at about $211,000. Two Sigma Investments LP bought a new position in shares of Ophthotech during the 4th quarter valued at about $367,000. Eversept Partners LLC bought a new position in shares of Ophthotech during the 4th quarter valued at about $465,000. Finally, Acadian Asset Management LLC bought a new position in shares of Ophthotech during the 4th quarter valued at about $622,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.
Ophthotech Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.